Skip to main content

 Scientific publications

Extended time interval between diagnosis and surgery does not improve the outcome in patients operated for resection or ablation of breast cancer liver metastases.

Authors : Lucidi V, Bohlok A, Liberale G, Bez M, Germanova D, Bouazza F, Demetter P, Larsimont D, Aftimos P, Smoll NR, Donckier V
Year : 2020
Journal : Eur J Surg Oncol
Volume : 46
Pages : 229-234

Lucitanib for the Treatment of HR<sup>+</sup>/HER2<sup>-</sup> Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study.

Authors : Hui R, Pearson A, Cortes J, Campbell C, Poirot C, Azim HA Jr, Fumagalli D, Lambertini M, Daly F, Arahmani A, Perez-Garcia J, Aftimos P, Bedard PL, Xuereb L, Scheepers ED, Vicente M, Goulioti T, Loibl S, Loi S, Pierrat MJ, Turner NC, Andre F, Curigliano G
Year : 2020
Journal : Clin Cancer Res
Volume : 26
Pages : 354-363

EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer.

Authors : Bardia A, Aftimos P, Bihani T, Anderson-Villaluz AT, Jung J, Conlan MG, Kaklamani VG
Year : 2019
Journal : Future Oncol
Volume : 15
Pages : 3209-3218

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.

Authors : Banerji U, van Herpen CML, Saura C, Thistlethwaite F, Lord S, Moreno V, Macpherson IR, Boni V, Rolfo C, de Vries EGE, Rottey S, Geenen J, Eskens F, Gil-Martin M, Mommers EC, Koper NP, Aftimos P
Year : 2019
Journal : Lancet Oncol
Volume : 20
Pages : 1124-1135

Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review.

Authors : Pondé N, Aftimos P, Piccart-Gebhart M
Year : 2019
Journal : Curr Treat Options Oncol
Volume : 20
Pages : 37

Network science in clinical trials: A patient-centered approach.

Authors : Manem VSK, Salgado R, Aftimos P, Sotiriou C, Haibe-Kains B
Year : 2018
Journal : Semin Cancer Biol
Volume : 52
Pages : 135-150

Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.

Authors : Bareche Y, Venet D, Ignatiadis M, Aftimos P, Piccart-Gebhart M, Rothé F, Sotiriou C
Year : 2018
Journal : Ann Oncol
Volume : 29(4)
Pages : 895-902

Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors.

Authors : Lewin J, Soria JC, Stathis A, Delord JP, Peters S, Awada A, Aftimos P, Bekradda M, Rezai K, Zeng Z, Hussain A, Perez S, Siu LL, Massard C
Year : 2018
Journal : J Clin Oncol
Volume : 36
Pages : 3007-3014

Celyad's novel CAR T-cell therapy for solid malignancies.

Authors : Lonez C, Hendlisz A, Shaza L, Aftimos P, Vouche M, Donckier V, Machiels JH, Van den Eynde M, Canon JL, Carrasco J, Odunsi K, Sahebjam S, Rottey S, Braun N, Verma B, Gilham DE, Lehmann FF
Year : 2018
Journal : Curr Res Transl Med
Volume : 66(2)
Pages : 53-56

Endocrine therapy and palbociclib within a compassionate use program in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer.

Authors : Maurer C, Ferreira AR, Martel S, Lambertini M, Pondé N, Aftimos P, de Azambuja E, Piccart-Gebhart M
Year : 2018
Journal : Breast
Volume : 39
Pages : 14-18

Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer.

Authors : Locatelli MA, Aftimos P, Dees EC, LoRusso PM, Pegram MD, Awada A, Huang B, Cesari R, Jiang Y, Shaik MN, Kern KA, Curigliano G
Year : 2017
Journal : Oncotarget
Volume : 8(2)
Pages : 2320-2328

The AURORA pilot study for molecular screening of patients with advanced breast cancer-a study of the breast international group.

Authors : Maetens M, Brown D, Irrthum A, Aftimos P, Viale G, Loibl S, Laes JF, Campbell PJ, Thompson A, Cortes J, Seiler S, Vinnicombe S, Oliveira M, Rothé F, Bareche Y, Fumagalli D, Zardavas D, Desmedt C, Piccart-Gebhart M, Loi S, Sotiriou C
Year : 2017
Journal : NPJ Breast Cancer
Volume : 3
Pages : 23

Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies.

Authors : Aftimos P, Rolfo C, Rottey S, Offner F, Bron D, Maerevoet M, Soria JC, Moshir M, Dreier T, Van Rompaey L, Michot JM, Silence K, Hultberg A, Gandini D, de Haard H, Ribrag V, Peeters M, Thibault A, Leupin N, Awada A
Year : 2017
Journal : Clin Cancer Res
Volume : 23(21)
Pages : 6411-6420

Adenoid cystic carcinoma of the breast - an aggressive presentation with pulmonary, kidney, and brain metastases: a case report.

Authors : Mhamdi HA, Kourie HR, Jungels C, Aftimos P, Belbaraka R, Piccart-Gebhart M
Year : 2017
Journal : J Med Case Rep
Volume : 11
Pages : 303

Charcot-Marie-Tooth hereditary neuropathy revealed after administration of docetaxel in advanced breast cancer.

Authors : Kourie HR, Mavroudakis N, Aftimos P, Piccart-Gebhart M
Year : 2017
Journal : World J Clin Oncol
Volume : 8
Pages : 425-428

Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types.

Authors : Lonez C, Verma B, Hendlisz A, Aftimos P, Awada A, Van Den Neste E, Catala G, Machiels JH, Piette F, Brayer JB, Sallman DA, Kerre T, Odunsi K, Davila ML, Gilham DE, Lehmann FF
Year : 2017
Journal : BMJ Open
Volume : 7(11)
Pages : e017075

Phase I dose-escalation study of plitidepsin in combination with bevacizumab in patients with refractory solid tumors.

Authors : Aspeslagh S, Awada A, S Matos-Pita A, Aftimos P, Bahleda R, Varga A, Soria JC
Year : 2016
Journal : Anticancer Drugs
Volume : 27
Pages : 1021-7

Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial.

Authors : Aftimos P, Polastro L, Ameye L, Jungels C, Vakili J, Paesmans M, van den Eerenbeemt J, Buttice A, Gombos A, de Valeriola D, Gil T, Piccart-Gebhart M, Awada A
Year : 2016
Journal : Eur J Cancer
Volume : 60
Pages : 117-124

Phase 2 Study of Trabectedin in Patients With Hormone Receptor-Positive, HER-2-Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene.

Authors : Awada A, Cortés J, Martín M, Aftimos P, Oliveira M, López-Tarruella S, Espie M, Lardelli P, Extremera S, Fernández-García EM, Delaloge S
Year : 2016
Journal : Clin Breast Cancer
Volume : 16(5)
Pages : 364-71

Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations.

Authors : Kourie HR, Chaix M, Gombos A, Aftimos P, Awada A
Year : 2016
Journal : Expert Opin Drug Metab Toxicol
Volume : 12(8)
Pages : 947-57